Skip to main content
Premium Trial:

Request an Annual Quote

OGT Acquires Sense Proteomic

NEW YORK (GenomeWeb News) – Oxford Gene Technology has acquired protein array firm Sense Proteomic for an undisclosed sum.

UK-based Sense Proteomic has identified biomarker panels for a variety of diseases including prostate cancer and lupus. According to OGT, Sense Proteomic's technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and also can be used to monitor response to therapeutic interventions.

"This deal, combined with our recent development of an ultra high throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance," OGT CEO Mike Evans said in a statement.